Ki-67 expression and its relation to molecular subgroups in primary endometrial cancer

Abstract Purpose Ki67 is an established biomarker in breast tumors but so far, its role in endometrial cancer biology has not been studied. Therefore, the aim of the current study is to evaluate the association of Ki​67 with molecular subgroups, ER status, and FIGO staging. Methods Patients with endometrial cancer were retrospectively included. Ki67 expression was immunohistochemically assessed as the percentage of positive tumor nuclei and categorized as < 10%, 10–20%, and > 20%. Statistical analyses included ANOVA with pairwise comparison, Kruskal–Wallis and Spearman’s rank correlation analyses. Results With a median overall Ki67 expression of 10% (range 1–90%), significant differences between the molecular subgroups were noted with highest Ki67 levels in p53abnormal tumors (32.5%, range 5–90%), followed by POLEmut tumors (25%, range 5–90%), dMMR tumors (13.5%, range 1–70%), and NSMP tumors (7%, range 1–85%). Within the NSMP subgroup, median Ki67 level in the 72 ER positive tumors was significantly lower to the 12 ER negative tumors and/or high-grade histology ( p = 0.005). A positive correlation for Ki67 with International Federation of Gynecology and Obstetrics (FIGO) stage was noted, with an even stronger association observed for the classification from 2023, compared to 2009 (rho = 0.45 vs. 0.41, both p < 0.01). Conclusion Ki67 expression varies significantly across endometrial cancer molecular subgroups and has a strong positive correlation to p53abnormal status, tumors with loss of ER expression, and advanced FIGO stage. Our findings suggest that combining Ki67 and ER status may serve as a valuable biomarker combination for stratification within the NSMP subgroup, supporting future prospective clinical validation.

Authors

Institutions

Publication Details

Journal
Journal of Cancer Research and Clinical Oncology
Published
2026-11-14
DOI
https://doi.org/10.1007/s00432-026-06650-2
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Ki-67 expression and its relation to molecular subgroups in primary endometrial cancer

Anca Chelariu-Raicu, Mirjana Kessler, Juliane Reichenbach, Nadia Harbeck et al.
Journal of Cancer Research and Clinical Oncology
Endometrial and Cervical Cancer Treatments
article

Ki-67 expression and its relation to molecular subgroups in primary endometrial cancer

Anca Chelariu-Raicu, Mirjana Kessler, Juliane Reichenbach, Nadia Harbeck, Alexander Burges, Frederick Klauschen, Bastian Czogalla, Doris Mayr, Susanne Beyer, Fabian Trillsch, Angelina Vlaški, Mara Franzl, John Kaldjob-Nloga, Sven Mahner
article en

Abstract

Abstract Purpose Ki67 is an established biomarker in breast tumors but so far, its role in endometrial cancer biology has not been studied. Therefore, the aim of the current study is to evaluate the association of Ki​67 with molecular subgroups, ER status, and FIGO staging. Methods Patients with endometrial cancer were retrospectively included. Ki67 expression was immunohistochemically assessed as the percentage of positive tumor nuclei and categorized as < 10%, 10–20%, and > 20%. Statistical analyses included ANOVA with pairwise comparison, Kruskal–Wallis and Spearman’s rank correlation analyses. Results With a median overall Ki67 expression of 10% (range 1–90%), significant differences between the molecular subgroups were noted with highest Ki67 levels in p53abnormal tumors (32.5%, range 5–90%), followed by POLEmut tumors (25%, range 5–90%), dMMR tumors (13.5%, range 1–70%), and NSMP tumors (7%, range 1–85%). Within the NSMP subgroup, median Ki67 level in the 72 ER positive tumors was significantly lower to the 12 ER negative tumors and/or high-grade histology ( p = 0.005). A positive correlation for Ki67 with International Federation of Gynecology and Obstetrics (FIGO) stage was noted, with an even stronger association observed for the classification from 2023, compared to 2009 (rho = 0.45 vs. 0.41, both p < 0.01). Conclusion Ki67 expression varies significantly across endometrial cancer molecular subgroups and has a strong positive correlation to p53abnormal status, tumors with loss of ER expression, and advanced FIGO stage. Our findings suggest that combining Ki67 and ER status may serve as a valuable biomarker combination for stratification within the NSMP subgroup, supporting future prospective clinical validation.

Journal of Cancer Research and Clinical Oncology
LMU Klinikum (DE), Pathologisches Institut (DE), Ludwig-Maximilians-Universität München (DE)
Endometrial and Cervical Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon